Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
US6599927B2 · kind B2 · utility
1Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2001 |
| Grant date | Jul 29, 2003 |
| Priority date | — |
| Expiry date | Apr 13, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.